STL Index for: Tazarotene
Tazarotene Lotion 0.045% for the Treatment of Acne (FP)
Topical retinoids are recommended as first-line therapy for most patients with acne. Tazarotene 0.045% lotion is a novel formulation that utilizes polymeric emulsion technology to improve tolerability and epidermal penetration.
Tazarotene Lotion 0.045% for the Treatment of Acne
Tazarotene 0.045% lotion is a novel formulation which utilizes polymeric emulsion technology to improve tolerability and epidermal penetration. Despite the lower concentration of tazarotene in the lotion formulation, which likely also contributes to improved tolerability, tazarotene 0.045% lotion is at least as effective as tazarotene 0.1% cream.
2021 Index for Skin Therapy Letter Volume 26 – Dermatology Edition
This index covers all articles published in Skin Therapy Letter Dermatology Edition articles in 2021. Articles are indexed by drug names, trade names and disease terms. Bold entries refer to major references.
How to Use Halobetasol Propionate and Tazarotene Lotion to Treat Psoriasis
A fixed combination halobetasol propionate and tazarotene lotion (HP/TAZ) was launched in Canada in 2020, to treat moderate to severe plaque psoriasis in adults. With the use of polymeric emulsion technology, there is uniform distribution of HP and TAZ and excipients on the skin and improved skin moisturization.
Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis
A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults.
Update on Drugs & Devices: September – October 2021
The update covers: Tazarotene lotion, 0.045% - Arazlo™ (Bausch Health), Anifrolumab-fnia IV use - Saphnelo™ (AstraZeneca), Immune globulin intravenous (human) 10% - Octagam® 10% (Octapharma), Odevixibat capsule - Bylvay™ (Albireo Pharma) and other treatments
Trifarotene: A New Topical Retinoid for the Treatment of Acne Vulgaris
A new topical retinoid, trifarotene, the first fourth-generation retinoid, is now available in Canada for the treatment of moderate facial and truncal acne.
Skin Treatments Introduced in 2019
A variety of new skin treatments introduced in 2019.
Update on Drugs & Devices: March – April 2020
This update covers Tazemetostat tablets/Tazverik™ (Epizyme, Inc.), Tazarotene lotion 0.045%/Arazlo™ (Ortho Dermatologics, Bausch Health) and Rituximab biosimilar for IV injection/ABP 798 (Amgen, Allergan).
A Clinician’s Guide to Treating Acne
In this article, we provide a guide to address a growing need by primary care physicians to have a logical and practical approach to treating various forms of acne.
The New Canadian Guideline for Acne Treatment
Physicians will be particularly reassured if the suggested guidelines are supported by scientific evidence. This new Canadian clinical guideline for the treatment of acne was developed taking into account new data published up to March 2015, as well as expert opinion and clinical experience.
Regulating Off-label Promotion of Medications: Has the Pendulum Swung Too Far?
Prescribing medications off-label is commonplace in dermatology. This article discusses the recent FDA policy chances, the debate on free speech, the benefits and risks of off label drug use and promotion, and how it relates to patient care.
Topical Management of Recalcitrant Psoriasis and Eczema
Psoriasis and eczema, especially atopic eczema, are two of the most common cutaneous conditions seen by family physicians and dermatologists. This article discusses the etiology of psoriasis and eczema, immunologic abnormalities, and the role of immune mediators.
Topical Therapy for the Management of Childhood Psoriasis: Part I
Psoriasis represents a potentially life-altering disease that can profoundly impact physical, emotional and social functioning, and overall quality of life. Part I of this 2-part series will focus on topical agents, their varying degrees of effectiveness, potential side-effects and applications in clinical practice.
Topical Treatment for Psoriasis
Topical treatments are usually the first line therapies for psoriasis. Corticosteroids, calcipotriol/calcupotriene, tazarotene, tars, and anthralin are discussed.
Combination therapy is both commonly used and effective in treating psoriasis. Common combinations like acitretin+light therapy, methotrexate+UVB, and tar+anthralin are discussed.
Treatment suggestions for different types of Psoriasis
Psoriasis types and subtypes can influence preferred treatment modality. This article discusses the symptoms specific to the psoriasis subtype, and considerations for selecting treatment.
Tazarotene as Acne Treatment Option
Tazarotene is a designer retinoid. It is approved by Health Canada as a treatment for psoriasis, acne, and photodamage. This article discussed its indications, side-effects, use, and drug interactions.
Tazarotene 0.1% Cream for the Treatment of Photodamage
Tazarotene (Tazorac®, Allergan) has been shown to be effective in reducing the effects of photoaging in short term studies. To determine its effectiveness in the longer term, a 24-week multicenter, double-blind, randomized, vehicle controlled intervention study of 563 patients with facial photodamage was carried out.
Topical Tazarotene Therapy for Psoriasis, Acne Vulgaris, and Photoaging
Psoriasis, acne vulgaris and photoaging are common conditions. Tazarotene is a pro-drug of tazarotenic acid, a receptor-selective retinoid, which has shown efficacy in the treatment of these disorders. In the treatment of acne vulgaris, it has greater comedolytic activity than the currently available topical retinoids.
With growing public reluctance to use systemic medications we can expect topical treatments for psoriasis and other skin conditions to become increasingly important in the future. These drugs are useful not only to control this disease, but also to limit the irritation caused by medications such as tazarotene and anthralin.
Update on Topical Acne Treatments
Topical acne treatment can positively benefit patients with acne. This review summarizes clinical and prescribing information on currently available topical agents. The efficacy of the medications included in this report is supported by properly designed randomized clinical trials.